About
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated...
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200, for Focal Segmental Glomerulosclerosis (FSGS), respiratory complications associated with COVID-19 and Diabetic Kidney Disease, and is developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). DMX-200 and DMX-700 were both identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology
  • 29
    Aug
    22
    News Release
    Preliminary final report
  • 18
    Aug
    22
    News Release
    CLARITY 2.0 COVID-19 Study Concludes Recruitment
  • 17
    Aug
    22
    Equity Research
    Dimerix (ASX:DXB) Research Update
  • 9
    Aug
    22
    News Release
    New Patent Family Application for DMX-700
  • 27
    Jul
    22
    News Release
    Dimerix quarterly activities report
  • 4
    Jul
    22
    News Release
    DMX-700 Study Shows Significant 80% Reduction in Lung Injury
  • 30
    Jun
    22
    Equity Research
    Dimerix (ASX:DXB) Research Initiation
  • 27
    Jun
    22
    News Release
    REMAP-CAP COVID-19 Study Analysis Update
  • 7
    Jun
    22
    News Release
    New Clinical Trial for DMX-200 in Diabetic Kidney Disease Patients
  • 6
    Jun
    22
    News Release
    Dimerix to Present at BIO International Convention
  • 1
    Jun
    22
    Company Presentation
    Dimerix Partnering and Investor Presentation
  • 18
    May
    22
    News Release
    Release of Shares from Voluntary Escrow
  • 12
    May
    22
    News Release
    Dimerix presents at Bioshares Biotech Summit
  • 9
    May
    22
    News Release
    FDA IND Approval for Phase 3 Study of DMX-200 in FSGS
  • 27
    Apr
    22
    News Release
    Dimerix Quarterly Activities Report
  • 29
    Mar
    22
    News Release
    Dimerix Receives A$3.7M R&D Tax Incentive Rebate
  • 29
    Mar
    22
    Company Presentation
    Dimerix Investor Presentation
  • 1
    Mar
    22
    News Release
    Dimerix Investor Call and Presentation
  • 28
    Feb
    22
    News Release
    DSMB Change to REMAP-CAP COVID-19 Study
  • 7
    Feb
    22
    News Release
    Chief Medical Officer Appointed to lead Clinical Development and Medical Affairs